Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
41.11
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 08, 2023
Via
ACCESSWIRE
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
September 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Apellis Pharmaceuticals Stands With Analysts
August 24, 2023
Via
Benzinga
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
September 05, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 04, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 04, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 04, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 04, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 02, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 02, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
September 02, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
September 01, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
September 01, 2023
Via
ACCESSWIRE
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – APLS
August 30, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
August 30, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 30, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
August 29, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and
Via
Benzinga
Catalent (CTLT) Stock Gains on Elliott Deal
August 29, 2023
Catalent (CTLT) stock is getting a boost on Tuesday after the company reached an agreement with Elliott Investment Management.
Via
InvestorPlace
Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts
August 29, 2023
Apellis Pharmaceuticals (APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
August 29, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
August 29, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
August 28, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, and Party City and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS
August 27, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
August 26, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
August 25, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action Lawsuit
August 24, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
3 Very Oversold Pharma Stocks to Buy Right Now
August 24, 2023
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.
Via
InvestorPlace
Apellis Pharma's Newly Launched Eye Drug Set For Resilient Performance, Syfovre Update Sparks Optimism
August 23, 2023
HC Wainwright says the relative lack of new cases is a positive and should jumpstart Apellis Pharmaceuticals Inc (NASDAQ: APLS) Syfovre,
Via
Benzinga
S&P 500 Gains 1%; Analog Devices Posts Downbeat Results
August 23, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Wednesday. The Dow traded up 0.51% to 34,462.61 while the NASDAQ rose 1.60% to 13,722.24....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.